STOCK TITAN

[Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Camp4 Therapeutics insider purchases reported by director and 10% owner Nashat Amir. On 09/11/2025 Polaris-affiliated entities purchased shares in a private placement at $1.53 per share under a Securities Purchase Agreement dated 09/09/2025. Purchases reported include 1,221,721 shares by Polaris Partners VII, L.P. and 85,468 shares by Polaris Entrepreneurs' Fund VII, L.P., with combined reported beneficial ownership following the transactions shown as 2,825,500 and 197,661 shares respectively and an additional 909,090 shares held indirectly by Polaris Partners X, L.P.

The filing discloses indirect ownership through management entities and contains standard disclaimers that the managing entities and reported persons disclaim beneficial ownership except to the extent of pecuniary interests.

Acquisti interni di Camp4 Therapeutics riportati dal direttore e titolare del 10% Nashat Amir. Il 09/11/2025 entità affiliate a Polaris hanno acquistato azioni in un collocamento privato a 1,53 dollari per azione ai sensi di un Accordo di Acquisto di Titoli datato 09/09/2025. Gli acquisti riportati includono 1.221.721 azioni da Polaris Partners VII, L.P. e 85.468 azioni da Polaris Entrepreneurs' Fund VII, L.P., con la proprietà beneficiaria combinata riportata dopo le transazioni indicata come 2.825.500 e 197.661 azioni rispettivamente, e ulteriori 909.090 azioni detenute indirettamente da Polaris Partners X, L.P.

La presentazione rivela proprietà indiretta tramite entità di gestione e contiene le avvertenze standard secondo cui le entità gestionali e le persone segnalate negano la proprietà benefica salvo che per interessi pecuniari.

Compras internas de Camp4 Therapeutics informadas por el director y titular del 10% Nashat Amir. El 09/11/2025, entidades afiliadas a Polaris adquirieron acciones en una colocación privada a 1,53 USD por acción conforme a un Acuerdo de Compra de Valores fechado el 09/09/2025. Las compras reportadas incluyen 1.221.721 acciones por Polaris Partners VII, L.P. y 85.468 acciones por Polaris Entrepreneurs' Fund VII, L.P., con la propiedad beneficiaria combinada reportada tras las transacciones mostrada como 2.825.500 y 197.661 acciones respectivamente, y 909.090 acciones adicionales mantenidas indirectamente por Polaris Partners X, L.P.

La presentación divulga propiedad indirecta a través de entidades de gestión y contiene las cláusulas de exención estándar que las entidades gestoras y las personas reportadas niegan la propiedad beneficiosa salvo al alcance de intereses pecuniarios.

Camp4 Therapeutics의 내부자 매매가 이사이자 10% 지분 보유자인 나샤트 아미르에 의해 보고되었습니다. 2025년 09/11/2025, Polaris 계열사가 2025/09/09에 작성된 증권 매매 계약에 따라 주당 1.53달러의 Private placement에서 주식을 매수했습니다. 보고된 매수에는 Polaris Partners VII, L.P.의 1,221,721주와 Polaris Entrepreneurs' Fund VII, L.P.의 85,468주가 포함되며 거래 후 합계 보유 지분은 각각 2,825,500주와 197,661주로 표시되며 Polaris Partners X, L.P.가 간접 보유한 추가 909,090주가 있습니다.

해당 공시는 경영진을 통한 간접 보유를 밝히며 관리 주체와 보고된 인물이 pecuniary interests 범위 내에서만 실질적 소유권을 주장한다는 표준 면책 조항을 포함합니다.

Achats d'initiés chez Camp4 Therapeutics rapportés par le directeur et propriétaire à 10% Nashat Amir. Le 09/11/2025, des entités affiliées à Polaris ont acheté des actions lors d'une placement privé à 1,53 $ par action en vertu d'un accord d'achat de titres daté du 09/09/2025. Les achats rapportés incluent 1 221 721 actions par Polaris Partners VII, L.P. et 85 468 actions par Polaris Entrepreneurs' Fund VII, L.P., avec une détention bénéficiaire combinée après les transactions indiquée comme 2 825 500 et 197 661 actions respectivement, et 909 090 actions détenues indirectement par Polaris Partners X, L.P.

Le dossier divulgue une propriété indirecte par le biais d'entités de gestion et contient les clauses de décharge standard selon lesquelles les entités gestionnaires et les personnes signalées nient toute propriété bénéficiaire, sauf dans la mesure des intérêts pécuniaires.

Interne Käufe bei Camp4 Therapeutics, gemeldet vom Direktor und 10%-Eigentümer Nashat Amir. Am 09/11/2025 kauften mit Polaris verbundene Einheiten Aktien in einer Privatplatzierung zu 1,53 USD pro Aktie gemäß einer am 09/09/2025 datierten Wertpapierkaufvereinbarung. Zu den gemeldeten Käufen gehören 1.221.721 Aktien von Polaris Partners VII, L.P. und 85.468 Aktien von Polaris Entrepreneurs' Fund VII, L.P., wobei die nach den Transaktionen gemeldete zusammengenommene wirtschaftliche Beteiligung 2.825.500 bzw. 197.661 Aktien beträgt und zusätzlich 909.090 Aktien indirekt von Polaris Partners X, L.P. gehalten werden.

Die Einreichung offenbart indirektes Eigentum über managementbezogene Einheiten und enthält Standardhaftungsausschlüsse, dass die verwaltenden Einheiten und die gemeldeten Personen kein wirtschaftliches Eigentum besitzen, außer insofern sie pecuniary interests betreffen.

شراءات داخلية لـ Camp4 Therapeutics أبلغ عنها المدير ومالك 10% ناشط أمير. في 09/11/2025 اشترت كيانات مرتبطة بـ Polaris أسهم في طرح خاص بسعر 1.53 دولار للسهم بموجب اتفاق شراء أوراق مالية مؤرخ 09/09/2025. تشمل المشتريات الموثقة 1,221,721 سهمًا من Polaris Partners VII, L.P. و85,468 سهمًا من Polaris Entrepreneurs' Fund VII, L.P.، مع الملكية المستفيدة المجمعة كما هو موضح بعد المعاملات بـ 2,825,500 و197,661 سهماً على التوالي، و909,090 سهماً إضافياً مملوكة بشكل غير مباشر من Polaris Partners X, L.P.

يكشف التفريغ عن الملكية غير المباشرة من خلال كيانات الإدارة ويتضمن شروط إفصاح قياسية بأن الكيانات الإدارية والأشخاص المبلغ عنهم ينكرون الملكية Beneficial إلا إلى الحد من المصالح المالية.

Camp4 Therapeutics 内部交易由董事兼10%股东Nashat Amir披露。 2025年 09/11/2025,与Polaris相关的实体按2025/09/09签署的证券购买协议,以每股1.53美元的价格在私募中购买股票。报告的买入包括Polaris Partners VII, L.P.的1,221,721股和Polaris Entrepreneurs' Fund VII, L.P.的85,468股,交易后合并持股分别为2,825,500股和197,661股,另外由Polaris Partners X, L.P间接持有的909,090股。

该披露通过管理实体显示间接所有权,并含有标准免责声明,即管理实体和披露的相关人仅在经济利益范围内对受益所有权作出声明。

Positive
  • Material insider participation in a private placement at $1.53 per share, showing continued backing from Polaris-affiliated funds
  • Clear disclosure of indirect ownership structures and post-transaction beneficial ownership amounts
Negative
  • None.

Insights

TL;DR: Significant private placement purchases at $1.53 per share by Polaris funds increase Polaris-related stakes in CAMP.

The transactions show material purchases by Polaris-affiliated limited partnerships in a private placement priced at $1.53 per share pursuant to a Securities Purchase Agreement dated 09/09/2025. Reported direct ownership amounts and the post-transaction beneficial ownership figures indicate sizable positions held indirectly through fund GP structures. This type of Form 4 signals continued investor support from existing institutional backers rather than open-market trading and is relevant to cap table and control dynamics.

TL;DR: Disclosure details indirect ownership via GP entities and includes customary disclaimers of beneficial ownership.

The filing carefully maps ownership through general partner and managing-member relationships and includes disclaimers that the managing members and management entities disclaim beneficial ownership except for pecuniary interests. The report is consistent with standard Section 16 reporting for fund-held positions and clarifies the reporting person’s role as director and 10% owner through affiliated entities.

Acquisti interni di Camp4 Therapeutics riportati dal direttore e titolare del 10% Nashat Amir. Il 09/11/2025 entità affiliate a Polaris hanno acquistato azioni in un collocamento privato a 1,53 dollari per azione ai sensi di un Accordo di Acquisto di Titoli datato 09/09/2025. Gli acquisti riportati includono 1.221.721 azioni da Polaris Partners VII, L.P. e 85.468 azioni da Polaris Entrepreneurs' Fund VII, L.P., con la proprietà beneficiaria combinata riportata dopo le transazioni indicata come 2.825.500 e 197.661 azioni rispettivamente, e ulteriori 909.090 azioni detenute indirettamente da Polaris Partners X, L.P.

La presentazione rivela proprietà indiretta tramite entità di gestione e contiene le avvertenze standard secondo cui le entità gestionali e le persone segnalate negano la proprietà benefica salvo che per interessi pecuniari.

Compras internas de Camp4 Therapeutics informadas por el director y titular del 10% Nashat Amir. El 09/11/2025, entidades afiliadas a Polaris adquirieron acciones en una colocación privada a 1,53 USD por acción conforme a un Acuerdo de Compra de Valores fechado el 09/09/2025. Las compras reportadas incluyen 1.221.721 acciones por Polaris Partners VII, L.P. y 85.468 acciones por Polaris Entrepreneurs' Fund VII, L.P., con la propiedad beneficiaria combinada reportada tras las transacciones mostrada como 2.825.500 y 197.661 acciones respectivamente, y 909.090 acciones adicionales mantenidas indirectamente por Polaris Partners X, L.P.

La presentación divulga propiedad indirecta a través de entidades de gestión y contiene las cláusulas de exención estándar que las entidades gestoras y las personas reportadas niegan la propiedad beneficiosa salvo al alcance de intereses pecuniarios.

Camp4 Therapeutics의 내부자 매매가 이사이자 10% 지분 보유자인 나샤트 아미르에 의해 보고되었습니다. 2025년 09/11/2025, Polaris 계열사가 2025/09/09에 작성된 증권 매매 계약에 따라 주당 1.53달러의 Private placement에서 주식을 매수했습니다. 보고된 매수에는 Polaris Partners VII, L.P.의 1,221,721주와 Polaris Entrepreneurs' Fund VII, L.P.의 85,468주가 포함되며 거래 후 합계 보유 지분은 각각 2,825,500주와 197,661주로 표시되며 Polaris Partners X, L.P.가 간접 보유한 추가 909,090주가 있습니다.

해당 공시는 경영진을 통한 간접 보유를 밝히며 관리 주체와 보고된 인물이 pecuniary interests 범위 내에서만 실질적 소유권을 주장한다는 표준 면책 조항을 포함합니다.

Achats d'initiés chez Camp4 Therapeutics rapportés par le directeur et propriétaire à 10% Nashat Amir. Le 09/11/2025, des entités affiliées à Polaris ont acheté des actions lors d'une placement privé à 1,53 $ par action en vertu d'un accord d'achat de titres daté du 09/09/2025. Les achats rapportés incluent 1 221 721 actions par Polaris Partners VII, L.P. et 85 468 actions par Polaris Entrepreneurs' Fund VII, L.P., avec une détention bénéficiaire combinée après les transactions indiquée comme 2 825 500 et 197 661 actions respectivement, et 909 090 actions détenues indirectement par Polaris Partners X, L.P.

Le dossier divulgue une propriété indirecte par le biais d'entités de gestion et contient les clauses de décharge standard selon lesquelles les entités gestionnaires et les personnes signalées nient toute propriété bénéficiaire, sauf dans la mesure des intérêts pécuniaires.

Interne Käufe bei Camp4 Therapeutics, gemeldet vom Direktor und 10%-Eigentümer Nashat Amir. Am 09/11/2025 kauften mit Polaris verbundene Einheiten Aktien in einer Privatplatzierung zu 1,53 USD pro Aktie gemäß einer am 09/09/2025 datierten Wertpapierkaufvereinbarung. Zu den gemeldeten Käufen gehören 1.221.721 Aktien von Polaris Partners VII, L.P. und 85.468 Aktien von Polaris Entrepreneurs' Fund VII, L.P., wobei die nach den Transaktionen gemeldete zusammengenommene wirtschaftliche Beteiligung 2.825.500 bzw. 197.661 Aktien beträgt und zusätzlich 909.090 Aktien indirekt von Polaris Partners X, L.P. gehalten werden.

Die Einreichung offenbart indirektes Eigentum über managementbezogene Einheiten und enthält Standardhaftungsausschlüsse, dass die verwaltenden Einheiten und die gemeldeten Personen kein wirtschaftliches Eigentum besitzen, außer insofern sie pecuniary interests betreffen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nashat Amir

(Last) (First) (Middle)
C/O POLARIS PARTNERS
ONE MARINA PARK DRIVE, 8TH FL.

(Street)
BOSTON MA 02210

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/11/2025 P(1) 1,221,721 A $1.53 2,825,500 I See Footnote(2)(3)
Common Stock 09/11/2025 P(1) 85,468 A $1.53 197,661 I See Footnote(4)
Common Stock 909,090 I See Footnote(5)(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.
2. The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, the Reporting Person, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII.
3. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
4. The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members, including the Reporting Person, disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members, including the Reporting Person, or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
5. The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). The Reporting Person, a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and the Reporting Person, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X.
6. Each of PPGP X, the PPGP X Managing Members and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, the Reporting Person or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
By: /s/ Lauren Crockett, Attorney-in-Fact 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions were reported on the Form 4 for CAMP?

On 09/11/2025 Polaris-affiliated funds acquired shares in a private placement at $1.53 per share pursuant to a Securities Purchase Agreement dated 09/09/2025.

How many shares did Polaris Partners VII and Polaris Entrepreneurs' Fund VII acquire in CAMP?

The filing reports 1,221,721 shares acquired by Polaris Partners VII and 85,468 shares acquired by Polaris Entrepreneurs' Fund VII.

What beneficial ownership totals are reported after the transactions?

Post-transaction beneficial ownership is reported as 2,825,500 shares (for the PP VII position) and 197,661 shares (for the PEF VII position), with an additional 909,090 shares held indirectly by Polaris Partners X, L.P.

What is Nashat Amir's relationship to CAMP as shown on the Form 4?

Nashat Amir is reported as a Director and a 10% Owner and is identified as a managing member of entities that may share voting, investment and dispositive power.

Were there any disclaimers about beneficial ownership in the filing?

Yes, the filing includes standard disclaimers that the management entities and managing members, including the reporting person, disclaim beneficial ownership except to the extent of pecuniary interests.
Camp4 Therapeutics Corp.

NASDAQ:CAMP

CAMP Rankings

CAMP Latest News

CAMP Latest SEC Filings

CAMP Stock Data

56.25M
11.81M
35.19%
51.76%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE